MetaCap

Anavex Life Sciences (AVXL) vs Neumora Therapeutics (NMRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Anavex Life Sciences (AVXL) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 81.9% versus a loss of 85.7%. Neumora Therapeutics is the larger company by market cap ($63.0 million vs $54.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVXL-81.86%NMRA-85.67%
+70%-12%-93%
Nov 21, 20251 yearNov 20, 2026
AVXL-92.19%NMRA-97.95%
+71%-17%-106%
Sep 11, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVXL versus NMRA key metrics
MetricAVXLNMRA
Share price$0.5915$0.3339
Market cap$54.83M$63.01M
1-day change-11.39%-3.78%
YTD return-83.38%-81.35%
1-year return-81.86%-85.67%
5-year return-96.96%—
EPS (TTM)$-0.14$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-46.38M$-236.93M
52-week high$5.36$3.65
52-week low$0.59$0.301
Distance from 52-week high-88.96%-90.85%
Analyst consensusnonebuy
Avg. price target upside—+1696.95%
Average volume1.15M1.69M
Shares outstanding92.70M188.69M
Employees3463
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About Neumora Therapeutics

NMRA stock →

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees

AVXL vs NMRA FAQ

Which is bigger, Anavex Life Sciences or Neumora Therapeutics?

Neumora Therapeutics (NMRA) is larger, with a market capitalization of $63.01M compared with $54.83M for Anavex Life Sciences (AVXL).

Which stock has performed better over the past year, AVXL or NMRA?

AVXL returned -81.86% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.

Are Anavex Life Sciences and Neumora Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons